yep, otherwise we can expect another dilution for the next stage of research...Some people are strictly research others business types. Meanwhile, we should be concerned of other potential screening tech that hits us like a bus.
I'll take a letter from a major insurance carrier putting out a bulletin proclaiming payment a and code. Until then it is a research company...
I rather wait for certainty at this point rather then hope. I still think the secondary was a disaster with a 30 % discount. It would not surprise me the shares have also been putted as a hedge.
Call it reality, we may have nothing but researchers in TROV. This stock has completely lagged behind the biotech sector of late. With so much promise one has to be paranoid. How many collaborations do they need to make a sale?
well, after increasing the collaborations from 5 to 15 the question is will that be reason to put collaborations on the back burner so now the focus is on creating revenue. If not, then this stock will go no where and be known as just another money pit for research that creates zero revenue.
It is the most spectacular scenery to ski with incredible vista's. From the top of the Kleine Matterhorn you look down to Zermatt and Cervinia (Italian Side). I have skied down to both towns several times. Gonergratt is also a good run to ski...I was lucky to ski many European destinations. Grindlewald is also spectacular as well Verbier.
Sentiment: Strong Buy
there in lies the problem "reasonable" argue that till your bankrupt. Governments could give a #$%$ about lives unless there is a means to control...Just like Obamacare..
who pays for testing? maybe buy 5 get 3 free? Developing world no way pay.